126 related articles for article (PubMed ID: 38685456)
1. Bioactive adrenomedullin as a marker of congestion and disease progression in patients with a systemic right ventricle.
Ansari Ramandi MM; Hendriks PM; Voors AA; van den Bosch AE; van Melle JP
Int J Cardiol; 2024 Aug; 408():132107. PubMed ID: 38685456
[TBL] [Abstract][Full Text] [Related]
2. Bio-adrenomedullin as a marker of congestion in patients with new-onset and worsening heart failure.
Ter Maaten JM; Kremer D; Demissei BG; Struck J; Bergmann A; Anker SD; Ng LL; Dickstein K; Metra M; Samani NJ; Romaine SPR; Cleland J; Girerd N; Lang CC; van Veldhuisen DJ; Voors AA
Eur J Heart Fail; 2019 Jun; 21(6):732-743. PubMed ID: 30843353
[TBL] [Abstract][Full Text] [Related]
3. Bioactive adrenomedullin for assessment of venous congestion in heart failure.
Egerstedt A; Czuba T; Bronton K; Lejonberg C; Ruge T; Wessman T; Rådegran G; Schulte J; Hartmann O; Melander O; Smith JG
ESC Heart Fail; 2022 Oct; 9(5):3543-3555. PubMed ID: 35903845
[TBL] [Abstract][Full Text] [Related]
4. Bioactive adrenomedullin a prognostic biomarker in patients with mild to moderate dyspnea at the emergency department: an observational study.
Bronton K; Wessman T; Gränsbo K; Schulte J; Hartmann O; Melander O
Intern Emerg Med; 2022 Mar; 17(2):541-550. PubMed ID: 34173962
[TBL] [Abstract][Full Text] [Related]
5. Biologically active adrenomedullin as a marker for residual congestion and early rehospitalization in patients hospitalized for acute heart failure: Data from STRONG-HF.
Voordes G; Davison B; Biegus J; Edwards C; Damman K; Ter Maaten J; Mebazaa A; Takagi K; Adamo M; Ambrosy AP; Arrigo M; Barros M; Celutkiene J; Čerlinskaitė-Bajorė K; Chioncel O; Cohen-Solal A; Damasceno A; Deniau B; Diaz R; Filippatos G; Gayat E; Kimmoun A; Lam CSP; Metra M; Novosadova M; Pagnesi M; Pang P; Ponikowski P; Saidu H; Sliwa K; Tomasoni D; Cotter G; Voors AA
Eur J Heart Fail; 2024 Jun; ():. PubMed ID: 38874185
[TBL] [Abstract][Full Text] [Related]
6. Adrenomedullin peptides and precursor levels in relation to haemodynamics and prognosis after heart transplantation.
Ahmed A; Kania K; Abdul Rahim H; Ahmed S; Rådegran G
ESC Heart Fail; 2023 Aug; 10(4):2427-2437. PubMed ID: 37246315
[TBL] [Abstract][Full Text] [Related]
7. Clinical value of pre-discharge bio-adrenomedullin as a marker of residual congestion and high risk of heart failure hospital readmission.
Pandhi P; Ter Maaten JM; Emmens JE; Struck J; Bergmann A; Cleland JG; Givertz MM; Metra M; O'Connor CM; Teerlink JR; Ponikowski P; Cotter G; Davison B; van Veldhuisen DJ; Voors AA
Eur J Heart Fail; 2020 Apr; 22(4):683-691. PubMed ID: 31797505
[TBL] [Abstract][Full Text] [Related]
8. Plasma bioactive adrenomedullin as a prognostic biomarker in acute heart failure.
Self WH; Storrow AB; Hartmann O; Barrett TW; Fermann GJ; Maisel AS; Struck J; Bergmann A; Collins SP
Am J Emerg Med; 2016 Feb; 34(2):257-62. PubMed ID: 26577429
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide as biomarkers for heart failure in young children with single ventricle congenital heart disease.
Lowenthal A; Camacho BV; Lowenthal S; Natal-Hernandez L; Liszewski W; Hills NK; Fineman JR; Bernstein HS
Am J Cardiol; 2012 Mar; 109(6):866-72. PubMed ID: 22196786
[TBL] [Abstract][Full Text] [Related]
10. Increased concentrations of bioactive adrenomedullin subsequently to angiotensin-receptor/neprilysin-inhibitor treatment in chronic systolic heart failure.
Arfsten H; Goliasch G; Bartko PE; Prausmüller S; Spinka G; Cho A; Novak J; Haslacher H; Strunk G; Struck J; Hülsmann M; Pavo N
Br J Clin Pharmacol; 2021 Mar; 87(3):916-924. PubMed ID: 32598074
[TBL] [Abstract][Full Text] [Related]
11. Adaptive cardiovascular hormones in a spectrum of heart failure phenotypes.
Zabarovskaja S; Hage C; Linde C; Daubert JC; Donal E; Gabrielsen A; Mellbin L; Lund LH
Int J Cardiol; 2015; 189():6-11. PubMed ID: 25885866
[TBL] [Abstract][Full Text] [Related]
12. The evaluation of the clinical utility of urocortin 1 and adrenomedullin versus proBNP in systolic heart failure.
Yıldırım E; Cengiz M; Yıldırım N; Aslan K; İpek E; Korkmaz AF; Ulusoy FR; Hatem E
Anatol J Cardiol; 2017 Mar; 17(3):184-190. PubMed ID: 25868038
[TBL] [Abstract][Full Text] [Related]
13. The Molar Ratio of N-terminal pro-B-type Natriuretic Peptide/B-type Natriuretic Peptide for Heart Failure-related Events in Stable Outpatients with Cardiovascular Risk Factors.
Suzuki S; Sugiyama S
Intern Med; 2018 Sep; 57(18):2621-2630. PubMed ID: 29709934
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular biomarkers predict post-discharge re-hospitalization risk and mortality among Swedish heart failure patients.
Molvin J; Jujic A; Bachus E; Gallo W; Tasevska-Dinevska G; Holm H; Melander O; Fedorowski A; Magnusson M
ESC Heart Fail; 2019 Oct; 6(5):992-999. PubMed ID: 31339668
[TBL] [Abstract][Full Text] [Related]
15. Mid-regional pro-adrenomedullin in patients with acute dyspnea: Data from the Akershus Cardiac Examination (ACE) 2 Study.
Pervez MO; Lyngbakken MN; Myhre PL; Brynildsen J; Langsjøen EC; Høiseth AD; Christensen G; Omland T; Røsjø H
Clin Biochem; 2017 May; 50(7-8):394-400. PubMed ID: 28065681
[TBL] [Abstract][Full Text] [Related]
16. Combining the use of amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the prognosis of hospitalized heart failure patients.
Wang Y; Zhang R; Huang Y; Zhai M; Zhou Q; An T; Huang Y; Zhao X; Tian P; Zhang Y; Zhang J
Clin Chim Acta; 2019 Apr; 491():8-14. PubMed ID: 30594544
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of plasma MR-proADM vs NT-proBNP for heart failure in people with type 2 diabetes: the SURDIAGENE prospective study.
Fraty M; Velho G; Gand E; Fumeron F; Ragot S; Sosner P; Mohammedi K; Gellen B; Saulnier PJ; Halimi JM; Montaigne D; Ducrocq G; Rehman M; Marre M; Roussel R; Hadjadj S;
Diabetologia; 2018 Dec; 61(12):2643-2653. PubMed ID: 30232509
[TBL] [Abstract][Full Text] [Related]
18. N-Terminal Pro-B-Type Natriuretic Peptide-Guided Therapy in Chronic Heart Failure Reduces Repeated Hospitalizations-Results From TIME-CHF.
Davarzani N; Sanders-van Wijk S; Karel J; Maeder MT; Leibundgut G; Gutmann M; Pfisterer ME; Rickenbacher P; Peeters R; Brunner-la Rocca HP
J Card Fail; 2017 May; 23(5):382-389. PubMed ID: 28232046
[TBL] [Abstract][Full Text] [Related]
19. Midregional proadrenomedullin and growth differentiation factor-15 are not influenced by obesity in heart failure patients.
Sinning C; Ojeda F; Wild PS; Schnabel RB; Schwarzl M; Ohdah S; Lackner KJ; Pfeiffer N; Michal M; Blettner M; Munzel T; Kempf T; Wollert KC; Kuulasmaa K; Blankenberg S; Salomaa V; Westermann D; Zeller T
Clin Res Cardiol; 2017 Jun; 106(6):401-410. PubMed ID: 28004184
[TBL] [Abstract][Full Text] [Related]
20. Circulating bioactive adrenomedullin as a marker of sepsis, septic shock and critical illness.
Lundberg OHM; Lengquist M; Spångfors M; Annborn M; Bergmann D; Schulte J; Levin H; Melander O; Frigyesi A; Friberg H
Crit Care; 2020 Nov; 24(1):636. PubMed ID: 33148300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
